What are the ICH QMS guidelines?

ICH Q10, Pharmaceutical Quality System, describes a comprehensive quality management model for pharmaceutical development and manufacturing. It applies throughout the product lifecycle, including pharmaceutical development, technology transfer, commercial manufacturing, and product discontinuation.

The guideline identifies four principal quality-system elements:
1. Process performance and product quality monitoring: Systems for evaluating whether processes remain controlled and products continue to meet established specifications.
2. Corrective and preventive action: Structured investigation of deviations, complaints, recalls, audit findings, and other quality problems to correct root causes and prevent recurrence.
3. Change management: Risk-based assessment, approval, implementation, and effectiveness review of changes affecting facilities, equipment, materials, processes, methods, or products.
4. Management review: Periodic senior-management evaluation of quality performance, emerging risks, resource requirements, and opportunities for improvement.

ICH Q10 also identifies knowledge management and quality risk management as important enabling tools. Senior management remains responsible for establishing the quality policy, assigning responsibilities, providing resources, overseeing outsourced activities, and promoting continual improvement.

Other ICH Quality Guidelines support the Q10 framework. ICH Q8 addresses pharmaceutical development, ICH Q9 addresses quality risk management, ICH Q12 covers lifecycle management and post-approval changes, and ICH Q14 addresses analytical procedure development.

ICH Q10 supplements—not replaces—national GMP requirements. Its concepts become regulatory expectations when adopted or implemented by authorities such as FDA, EMA, or other ICH-member regulators.